Bristol-Myers Squibb Company

NYSE:BMY

Drug Manufacturers - General

Healthcare
$59.56 -2.57%

-$1.42 today

Market cap
$121.75B
Beta
0.24
P/E (TTM)
15.1
EPS (TTM)
$3.56
Dividend yield
4.64%
52W Low $42.52High $62.89

Volume 9.54M

Average 11.50M

BMY Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Bristol-Myers Squibb CompanyNYSE: BMY

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization declines year over year

Q2 FY2026 depreciation & amortization of $594M fell 41.2% year over year, ahead of the -51.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -26.9% a year.

Context

  • Depreciation & amortization amounted to 8.3% of revenue in FY2025, down 11.6 pp from a year earlier.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -41.2% holds above the trailing-twelve-month pace of -51.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$594M+0.0% QoQ
Last fiscal yearDec 2025
$4.01B-58.2% YoY
LTMJun 2026
$3.18B-51.1% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-41.2%——
1 year-58.2%——
3-year CAGR-26.9%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
4.01B USD
Year-over-year change
-58.2%
4-year CAGR
-21.7%

Depreciation & Amortization vs competitors

How BMY compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -51.1% is the lowest of 11, against a peer median of -7.0%.
  • Depreciation & amortization amounts to 6.5% of revenue for BMY, versus a peer median of 9.3%.
BMY Competitors
Depreciation & Amortization for BMY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$6.72B USD+45.9%+14.3%10.1%
PFEPfizer Inc.LTM Jun 2026$6.58B USD-3.0%+9.2%10.3%
AZNAstraZeneca PLCLTM Sep 2026$6.41B USD+29.8%+3.0%10.3%
JNJJohnson & JohnsonLTM Sep 2026$5.97B USD-19.1%+2.5%6.0%
ABBVAbbVie Inc.LTM Sep 2026$5.81B USD-29.7%-1.3%8.8%
NVSNovartis AGLTM Jun 2026$5.34B USD-11.0%-7.2%9.6%
AMGNAmgen Inc.LTM Jun 2026$4.67B USD-15.5%+14.8%12.2%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$3.18B USD-51.1%-26.9%6.5%
GILDGilead Sciences, Inc.LTM Jun 2026$2.76B USD-0.4%+9.5%9.1%
GSKGSK plcLTM Jun 2026£2.21B GBP-34.0%+2.5%6.7%
LLYEli Lilly and CompanyLTM Jun 2026$2.1B USD+10.9%+9.5%2.6%
Peer median (excluding BMY) —-7.0%+6.1%9.3%

Competitors are the stored peer set for BMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue46.39B46.16B45.01B48.3B48.2B
Cost of Revenue9.94B10.14B10.69B13.97B13.94B
Gross Profit36.45B36.02B34.31B34.33B34.26B
Gross Margin78.6%78.0%76.2%71.1%71.1%
Research & Development10.2B9.51B9.3B11.16B9.95B
Selling, General & Admin7.69B7.81B7.77B8.41B7.27B
Operating Expenses27.91B26.92B26.12B28.45B20.54B
Depreciation & Amortization10.69B10.28B9.76B9.6B4.01B
EBITDA20.12B19.22B19.37B3.17B15.23B
EBITDA Margin43.4%41.6%43.0%6.6%31.6%
Operating Income8.54B9.1B8.2B5.89B13.72B
Operating Margin18.4%19.7%18.2%12.2%28.5%
Interest Income00000
Interest Expense1.33B1.23B1.17B1.95B1.89B
Other Income / Expenses(439M)(1.39B)245M(14.27B)(4.4B)
Income Before Tax8.1B7.71B8.44B(8.38B)9.33B
Pre-Tax Margin17.5%16.7%18.8%-17.3%19.4%
Income Tax Expense1.08B1.37B400M554M2.27B
Net Income6.99B6.33B8.03B(8.95B)7.05B
Net Margin15.1%13.7%17.8%-18.5%14.6%
EPS (Basic)3.152.973.88(4.41)3.46
EPS (Diluted)3.122.953.86(4.41)3.45
Weighted Avg Shares2.22B2.13B2.07B2.03B2.04B
Weighted Avg Shares (Diluted)2.25B2.15B2.08B2.03B2.04B

Bristol-Myers Squibb Company

NYSE:BMY

Intrinsic Alpha fair value

Locked

Current Price

$59.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.